Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
Prithviraj Bose
Leukemia
Research output
:
Contribution to journal
›
Review article
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
INCB018424
100%
Primary Myelofibrosis
80%
Janus Kinase Inhibitors
25%
Neoplasms
20%
imetelstat
18%
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
18%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
17%
Fedratinib
17%
Janus Kinase 1
14%
Activin Receptors
13%
Janus Kinase 2
12%
Therapeutics
10%
Expert Testimony
9%
Anemia
7%
Spleen
7%
Alleles
6%
Ligands
6%
Survival
5%
Pharmaceutical Preparations
3%
Social Sciences
bone marrow
47%
expert opinions
37%
drug
21%